Dr. van Ballegooijen’s research is focused on decision-making concerning cancer screening, on basis of optimization of screening strategies from a cost-effectiveness point of view. In most of the projects she worked on, the MISCAN simulation program was used for the analysis of screening and epidemiologic data and the prediction of effects and costs.
Sally W.Vernon, M.A., Ph.D., Dr. Vernon is Professor of Behavioral Sciences and Epidemiology, Director of the Division of Health Promotion and Behavioral Sciences, and Senior Investigator in the Center for Health Promotion and Prevention Research, University of Texas-Houston, School of Public Health.
Her training is in epidemiology and behavioral sciences. Her interdisciplinary training has led to a research focus on translating epidemiologic evidence and principles to the design and evaluation of interventions to encourage the adoption of health behaviors. Her research interests encompass the epidemiology of mental disorders, with a particular focus on racial/ethnic differences in conceptualization and measurement; the analysis of psychosocial factors as predictors of health behaviors and health status indicators; and the design and evaluation of interventions to encourage adoption of cancer screening behaviors. Over the past 15 years, Dr. Vernon has published extensively in the area of cancer prevention and control with an emphasis on the primary and secondary prevention of breast, cervical, and colorectal cancers. More recently, she has worked in the area of informed consent and informed decision making about testing with the prostate specific antigen. In her recent work she has applied findings from epidemiologic studies to develop interventions to increase regular cancer screening behaviors, for cancers where the epidemiologic evidence supports the use of screening tests (e.g., cervical cancer) or to educate physicians and patients about the risks and benefits of tests with uncertain efficacy (e.g., prostate specific antigen).
Sandeep Vijan, M.D., M.S., is a Physician-Scientist at the Ann Arbor VA HSR&D Center of Excellence and an Assistant Professor of Internal Medicine at the University of Michigan Medical School. His research interests include evaluating the effectiveness and cost-effectiveness of preventive interventions in primary care, particularly those related to screening for common diseases and disease complications. He is also involved in evaluating methods of tailoring interventions based on individualized assessments of patient risks and preferences. Although he has a broad range of disease interests, his research has been primarily focused on diabetes and colorectal cancer.
Judith L.Wagner, Ph.D., Judith Wagner, Ph.D. has been a Scholar in Residence at the Institute of Medicine since January 2003. She has more than 30 years experience in health policy analysis and health technology economics. Most recently, as a Senior Analyst at the Congressional Budget Office, she specialized in prescription drug issues, including the design of a Medicare prescription drug benefit, Medicaid drug payment, and reform of current laws governing the entry of generic drugs into the market place. Before joining CBO, she was a consultant at the Mayo Clinic in Rochester, MN, where she conducted cost and cost-effectiveness analyses of medical procedures and technologies for both research and operational planning at the Clinic. She also managed major assessments of the cost-effectiveness of preventive and diagnostic technologies at the U.S. Congress Office of Technology Assessment, including studies of the cost-effectiveness of colorectal cancer screening in average-risk adults. Dr. Wagner holds a Ph.D. from Cornell University, where she studied economics and operations research with emphasis on environmental applications. She also holds master’s degrees in economics from the University of Michigan and in environmental systems engineering from Cornell University.